Amedeo Smart

Free Medical Literature Service


 

Amedeo

Ischemic Heart Disease

  Free Subscription

Articles published in
Lancet
    December 2023
  1. JIMENEZ DIAZ VA, Iniguez Romo A
    Intracoronary artery visualisation of crystalline sirolimus deposits after drug-coated balloon angioplasty for acute coronary syndrome.
    Lancet. 2023;402:2111-2112.
    >> Share

    November 2023
  2. ZAMAN M, de Vale ML, Coultas C, Goff L, et al
    Factors affecting the delivery of community-based salon interventions to prevent cardiovascular disease and breast cancer among ethnically diverse women in South London: a concept-mapping approach.
    Lancet. 2023;402 Suppl 1:S96.
    >> Share

  3. KHAN Y, Verhaeghe N, Devleesschauwer B, Cavillot L, et al
    Impact of the COVID-19 pandemic on delayed care of cardiovascular diseases in Europe: a systematic review.
    Lancet. 2023;402 Suppl 1:S61.
    >> Share

    October 2023
  4. IGLESIAS JF, Roffi M, Losdat S, Muller O, et al
    Long-term outcomes with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in ST-segment elevation myocardial infarction: 5-year follow-up of the BIOSTEMI randomised superiority trial.
    Lancet. 2023 Oct 25:S0140-6736(23)02197-9. doi: 10.1016/S0140-6736(23)02197.
    >> Share

  5. BUITEN RA, Ploumen EH
    Drug-eluting stents for ST-segment elevation myocardial infarction: extending the biodegradable versus durable polymer debate.
    Lancet. 2023 Oct 25:S0140-6736(23)02297-3. doi: 10.1016/S0140-6736(23)02297.
    >> Share

  6. ZEYMER U, Freund A, Hochadel M, Ostadal P, et al
    Venoarterial extracorporeal membrane oxygenation in patients with infarct-related cardiogenic shock: an individual patient data meta-analysis of randomised trials.
    Lancet. 2023;402:1338-1346.
    >> Share

    September 2023
  7. HEYMANS S, Lakdawala NK, Tschope C, Klingel K, et al
    Dilated cardiomyopathy: causes, mechanisms, and current and future treatment approaches.
    Lancet. 2023;402:998-1011.
    >> Share

    August 2023
  8. DILETTI R, den Dekker WK, Elscot JJ, Boersma E, et al
    Complete revascularisation in patients with acute coronary syndrome - Authors' reply.
    Lancet. 2023;402:612.
    >> Share

  9. DE CARLO M, Petronio AS, De Caterina R
    Complete revascularisation in patients with acute coronary syndrome.
    Lancet. 2023;402:611-612.
    >> Share

  10. XU X, Zhu H, Chen T, Cai L, et al
    Complete revascularisation in patients with acute coronary syndrome.
    Lancet. 2023;402:611.
    >> Share

  11. SHAH R
    Complete revascularisation in patients with acute coronary syndrome.
    Lancet. 2023;402:610-611.
    >> Share

    July 2023
  12. JEE J
    Machine learning-based markers for CAD.
    Lancet. 2023;402:183.
    >> Share

  13. ELLIOTT A, Pirruccello JP
    Machine learning-based markers for CAD.
    Lancet. 2023;402:182-183.
    >> Share

  14. YU L
    Machine learning-based markers for CAD.
    Lancet. 2023;402:182.
    >> Share

    April 2023
  15. GAUDINO M, Andreotti F, Kimura T
    Current concepts in coronary artery revascularisation.
    Lancet. 2023 Apr 27:S0140-6736(23)00459-2. doi: 10.1016/S0140-6736(23)00459.
    >> Share

    March 2023
  16. DILETTI R, den Dekker WK, Bennett J, Schotborgh CE, et al
    Immediate versus staged complete revascularisation in patients presenting with acute coronary syndrome and multivessel coronary disease (BIOVASC): a prospective, open-label, non-inferiority, randomised trial.
    Lancet. 2023 Mar 3:S0140-6736(23)00351-3. doi: 10.1016/S0140-6736(23)00351.
    >> Share

  17. RIDKER PM, Bhatt DL, Pradhan AD, Glynn RJ, et al
    Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials.
    Lancet. 2023 Mar 3:S0140-6736(23)00215-5. doi: 10.1016/S0140-6736(23)00215.
    >> Share

  18. TARDIF JC, Samuel M
    Inflammation contributes to cardiovascular risk in patients receiving statin therapy.
    Lancet. 2023 Mar 3:S0140-6736(23)00454-3. doi: 10.1016/S0140-6736(23)00454.
    >> Share

  19. PUSTJENS TFS, Vriesendorp PA, Van't Hof AWJ
    Revascularisation in acute coronary syndromes: change in practice?
    Lancet. 2023 Mar 3:S0140-6736(23)00403-8. doi: 10.1016/S0140-6736(23)00403.
    >> Share

  20. HE J, Ouyang N, Guo X, Sun G, et al
    Effectiveness of a non-physician community health-care provider-led intensive blood pressure intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial.
    Lancet. 2023 Mar 2:S0140-6736(22)02603-4. doi: 10.1016/S0140-6736(22)02603.
    >> Share

  21. YAN LL, Karmacharya BM
    Improving cardiovascular health in rural China and beyond.
    Lancet. 2023 Mar 2:S0140-6736(23)00092-2. doi: 10.1016/S0140-6736(23)00092.
    >> Share

    February 2023
  22. WANG Y, Li S, Pan Y, Li H, et al
    Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial.
    Lancet. 2023 Feb 8:S0140-6736(22)02600-9. doi: 10.1016/S0140-6736(22)02600.
    >> Share

  23. MENON BK, Singh N, Sylaja PN
    Tenecteplase use in patients with acute ischaemic stroke.
    Lancet. 2023 Feb 8:S0140-6736(22)02633-2. doi: 10.1016/S0140-6736(22)02633.
    >> Share

    January 2023
  24. TAWFIQ E, Selak V, Elwood JM, Pylypchuk R, et al
    Performance of cardiovascular disease risk prediction equations in more than 14 000 survivors of cancer in New Zealand primary care: a validation study.
    Lancet. 2023 Jan 23:S0140-6736(22)02405-9. doi: 10.1016/S0140-6736(22)02405.
    >> Share

  25. ROSSELLO X
    Cardiovascular risk assessment in survivors of cancer.
    Lancet. 2023 Jan 23:S0140-6736(22)02582-X. doi: 10.1016/S0140-6736(22)02582.
    >> Share

  26. WENZL FA, Luscher TF
    Application of a sex-specific GRACE score in practice - Authors' reply.
    Lancet. 2023;401:23.
    >> Share

  27. KIMENAI DM, Mills NL
    Application of a sex-specific GRACE score in practice.
    Lancet. 2023;401:22-23.
    >> Share

  28. CONRAD N, McMurray JJV
    Cardiovascular risk in systemic autoimmune diseases - Authors' reply.
    Lancet. 2023;401:22.
    >> Share

  29. FUNADA S, Luo Y, Nishioka N, Yoshioka T, et al
    Cardiovascular risk in systemic autoimmune diseases.
    Lancet. 2023;401:21.
    >> Share

  30. CAFARO G, Perricone C, Gerli R, Bartoloni E, et al
    Cardiovascular risk in systemic autoimmune diseases.
    Lancet. 2023;401:21-22.
    >> Share

    December 2022
  31. BATRA P, Khera AV
    Machine learning to assess coronary artery disease status-is it helpful?
    Lancet. 2022 Dec 20:S0140-6736(22)02584-3. doi: 10.1016/S0140-6736(22)02584.
    >> Share

  32. FORREST IS, Petrazzini BO, Duffy A, Park JK, et al
    Machine learning-based marker for coronary artery disease: derivation and validation in two longitudinal cohorts.
    Lancet. 2022 Dec 20:S0140-6736(22)02079-7. doi: 10.1016/S0140-6736(22)02079.
    >> Share

    November 2022
  33. COUGHLAN JJ, Kastrati A
    Bivalirudin in patients with ST-segment elevation myocardial infarction.
    Lancet. 2022 Nov 4. pii: S0140-6736(22)02162.
    >> Share

  34. LI Y, Liang Z, Qin L, Wang M, et al
    Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial.
    Lancet. 2022 Nov 4. pii: S0140-6736(22)01999.
    >> Share

    October 2022
  35. MACKENZIE IS, Rogers A, Poulter NR, Williams B, et al
    Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial.
    Lancet. 2022 Oct 11. pii: S0140-6736(22)01786.
    >> Share

  36. MACKENZIE IS, Hawkey CJ, Ford I, Greenlaw N, et al
    Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial.
    Lancet. 2022;400:1195-1205.
    >> Share

  37. NI AINLE F, Middeldorp S, Le Gal G, Hunt BJ, et al
    Protecting patients during a shortage of thrombolytic agents.
    Lancet. 2022;400:1193-1194.
    >> Share

  38. TANAKA A, Node K
    Xanthine oxidase inhibition for cardiovascular disease prevention.
    Lancet. 2022;400:1172-1173.
    >> Share

    September 2022
  39. WALLI-ATTAEI M, Rosengren A, Rangarajan S, Breet Y, et al
    Metabolic, behavioural, and psychosocial risk factors and cardiovascular disease in women compared with men in 21 high-income, middle-income, and low-income countries: an analysis of the PURE study.
    Lancet. 2022;400:811-821.
    >> Share

  40. MANFRINI O, Bugiardini R
    Behavioural risk factors and cardiovascular disease: are women at higher risk?
    Lancet. 2022;400:788-789.
    >> Share

    August 2022
  41. WENZL FA, Kraler S, Ambler G, Weston C, et al
    Sex-specific evaluation and redevelopment of the GRACE score in non-ST-segment elevation acute coronary syndromes in populations from the UK and Switzerland: a multinational analysis with external cohort validation.
    Lancet. 2022 Aug 26. pii: S0140-6736(22)01483.
    >> Share

  42. DE MIGUEL-BALSA E
    Risk stratification and health inequalities in women with acute coronary syndrome: time to move on.
    Lancet. 2022 Aug 26. pii: S0140-6736(22)01607.
    >> Share

  43. CONRAD N, Verbeke G, Molenberghs G, Goetschalckx L, et al
    Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK.
    Lancet. 2022 Aug 26. pii: S0140-6736(22)01349.
    >> Share

    July 2022
  44. KIM BK, Hong SJ, Lee YJ, Hong SJ, et al
    Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial.
    Lancet. 2022 Jul 18. pii: S0140-6736(22)00916.
    >> Share

    June 2022
  45. SANDSET EC, Tsvigoulis G
    Tenecteplase for acute ischaemic stroke.
    Lancet. 2022 Jun 28. pii: S0140-6736(22)01107.
    >> Share

  46. MENON BK, Buck BH, Singh N, Deschaintre Y, et al
    Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial.
    Lancet. 2022 Jun 28. pii: S0140-6736(22)01054.
    >> Share

    May 2022
  47. DELGADO-LISTA J, Alcala-Diaz JF, Torres-Pena JD, Quintana-Navarro GM, et al
    Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial.
    Lancet. 2022 May 4. pii: S0140-6736(22)00122.
    >> Share

    April 2022
  48. BERGMARK BA, Mathenge N, Merlini PA, Lawrence-Wright MB, et al
    Acute coronary syndromes.
    Lancet. 2022;399:1347-1358.
    >> Share

    February 2022
  49. BODEN WE, Kaski JC, Al-Lamee R, Weintraub WS, et al
    What constitutes an appropriate empirical trial of antianginal therapy in patients with stable angina before referral for revascularisation?
    Lancet. 2022;399:691-694.
    >> Share

    November 2021
  50. CALDEIRA D, Pinto FJ
    COVID-19 and myocardial infarction.
    Lancet. 2021;398:1963-1964.
    >> Share

  51. KATSOULARIS I, Fonseca-Rodriguez O, Farrington P, Lindmark K, et al
    COVID-19 and myocardial infarction - Authors' reply.
    Lancet. 2021;398:1964.
    >> Share

  52. SABATINE MS, Bergmark BA, Murphy SA, O'Gara PT, et al
    Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis.
    Lancet. 2021 Nov 12. pii: S0140-6736(21)02334.
    >> Share

  53. MEHRAN R, Owen R, Chiarito M, Baber U, et al
    A contemporary simple risk score for prediction of contrast-associated acute kidney injury after percutaneous coronary intervention: derivation and validation from an observational registry.
    Lancet. 2021 Nov 12. pii: S0140-6736(21)02326.
    >> Share

  54. BELLEY-COTE EP, Devereaux PJ
    PCI versus CABG for left main coronary artery disease: is the jury still out?
    Lancet. 2021 Nov 12. pii: S0140-6736(21)02491.
    >> Share

  55. KANG J, Koo BK, Park KW, Shin ES, et al
    Aspirin versus clopidogrel after percutaneous coronary intervention - Authors' reply.
    Lancet. 2021;398:1685-1686.
    >> Share

  56. PAREEK M, Byrne C
    Aspirin versus clopidogrel after percutaneous coronary intervention.
    Lancet. 2021;398:1685.
    >> Share

  57. BYRNE RA, McGovern L
    Angiography-derived quantitative flow ratio guidance of coronary intervention: measure twice, cut once.
    Lancet. 2021 Nov 3. pii: S0140-6736(21)02397.
    >> Share

  58. XU B, Tu S, Song L, Jin Z, et al
    Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial.
    Lancet. 2021 Nov 3. pii: S0140-6736(21)02248.
    >> Share

    October 2021
  59. DEL PRATO S, Kahn SE, Pavo I, Weerakkody GJ, et al
    Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
    Lancet. 2021 Oct 18. pii: S0140-6736(21)02188.
    >> Share

  60. KIM CJ, Park MW, Kim MC, Choo EH, et al
    Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised tr
    Lancet. 2021;398:1305-1316.
    >> Share

  61. TSAMPASIAN V, Maart C, Vassiliou VS, Garg P, et al
    Mitral valve disease in sarcoidosis diagnosed by cardiovascular magnetic resonance.
    Lancet. 2021;398:1358.
    >> Share

    September 2021
  62. PINTO FJ, Pineiro D, Banerjee A, Perel P, et al
    World Heart Day 2021: COVID-19, digital health, and tackling cardiovascular disease.
    Lancet. 2021 Sep 28. pii: S0140-6736(21)02144.
    >> Share


  63. Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC).
    Lancet. 2021 Sep 7. pii: S0140-6736(21)01122.
    >> Share

    March 2021
  64. LONNEBAKKEN MT
    The risk of no risk in STEMI.
    Lancet. 2021;397:1039-1040.
    >> Share

  65. FIGTREE GA, Vernon ST, Hadziosmanovic N, Sundstrom J, et al
    Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data.
    Lancet. 2021;397:1085-1094.
    >> Share

    February 2021
  66. TAKAHASHI K, van Klaveren D, Steyerberg EW, Onuma Y, et al
    Concerns with the new SYNTAX score - Authors' reply.
    Lancet. 2021;397:795-796.
    >> Share

  67. FREEMANTLE N, Pagano D
    Concerns with the new SYNTAX score.
    Lancet. 2021;397:795.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016